ERBB2 and breast neoplasm: In women with healthy weight, current EPT users were more likely to be diagnosed with luminal A–like (OR, 2.51 [95% CI, 2.26-2.80]), luminal B–like (OR, 1.47 [95% CI, 1.17-1.86]), or luminal B–ERBB2–like (OR, 1.95 [95% CI, 1.61-2.37]) breast tumors, with significant heterogeneity across subtypes (P < .001 for heterogeneity).